Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Inverness, Matritech deal

IMA will acquire substantially all of MZT's assets for $36 million in stock,

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE